These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28237530)

  • 21. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
    Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective development of a prostate cancer risk calculator in a racially diverse population: The Kaiser Permanente Prostate Cancer Risk Calculator.
    Presti J; Alexeeff S; Horton B; Prausnitz S; Avins AL
    Urol Oncol; 2020 Nov; 38(11):847.e1-847.e8. PubMed ID: 32536468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
    Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
    J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.
    Zhu Y; Wang JY; Shen YJ; Dai B; Ma CG; Xiao WJ; Lin GW; Yao XD; Zhang SL; Ye DW
    Asian J Androl; 2012 Sep; 14(5):738-44. PubMed ID: 22561907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
    Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
    BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
    Nguyen CT; Yu C; Moussa A; Kattan MW; Jones JS
    J Urol; 2010 Feb; 183(2):529-33. PubMed ID: 20006887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
    Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ; Thompson IM
    Urology; 2014 Jun; 83(6):1362-7. PubMed ID: 24862395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective validation of the Kaiser Permanente prostate cancer risk calculator in a contemporary, racially diverse, referral population.
    Presti JC; Alexeeff S; Horton B; Prausnitz S; Avins AL
    Urol Oncol; 2021 Nov; 39(11):783.e11-783.e19. PubMed ID: 33962850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer risk prediction in a urology clinic in Mexico.
    Liang Y; Messer JC; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Oncol; 2013 Oct; 31(7):1085-92. PubMed ID: 22306115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
    Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
    BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.
    Wu YS; Zhang N; Liu SH; Xu JF; Tong SJ; Cai YH; Zhang LM; Bai PD; Hu MB; Jiang HW; Na R; Ding Q; Sun YH
    Asian J Androl; 2016; 18(6):925-929. PubMed ID: 27212127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.
    Loeb S; Shin SS; Broyles DL; Wei JT; Sanda M; Klee G; Partin AW; Sokoll L; Chan DW; Bangma CH; van Schaik RHN; Slawin KM; Marks LS; Catalona WJ
    BJU Int; 2017 Jul; 120(1):61-68. PubMed ID: 27743489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools.
    Tolksdorf J; Kattan MW; Boorjian SA; Freedland SJ; Saba K; Poyet C; Guerrios L; De Hoedt A; Liss MA; Leach RJ; Hernandez J; Vertosick E; Vickers AJ; Ankerst DP
    BMC Med Res Methodol; 2019 Oct; 19(1):191. PubMed ID: 31615451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
    Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
    Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
    Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptation of the prostate biopsy collaborative group risk calculator in patients with PSA less than 10 ng/ml improves its performance.
    Stojadinovic M; Trifunovic T; Jankovic S
    Int Urol Nephrol; 2020 Oct; 52(10):1811-1819. PubMed ID: 32468165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
    Luckenbaugh AN; Auffenberg GB; Hawken SR; Dhir A; Linsell S; Kaul S; Miller DC;
    J Urol; 2017 Mar; 197(3 Pt 1):621-626. PubMed ID: 27663459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.
    Strobl AN; Thompson IM; Vickers AJ; Ankerst DP
    J Urol; 2015 Jul; 194(1):58-64. PubMed ID: 25636656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
    World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.